Collaborative innovation in drug discovery : strategies for public and private partnerships / / edited by Dr. Rathnam Chaguturu ; Nobel Laureate Ferid Murad, foreword ; contributors Khusru Asadullah [and sixty four others]

• Record Nr.: UNINA9910815052503321
• Pubbl/distr/stampa: Hoboken, New Jersey : , : Wiley, , 2014; ©2014
• ISBN: 1-118-77816-2; 1-118-77815-4
• Descrizione fisica: 1 online resource (760 p.)
• Collana: Wiley Series on Technologies for the Pharmaceutical Industry
• Disciplina: 615.1/9
• Soggetti: Drug Discovery; Public-Private Sector Partnerships; Drug development; Public-private sector cooperation
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references at the end of each chapters and index.
• Nota di contenuto: Cover; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Contents; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; Land Grants; Investments in Research; Intellectual Property; Impact on U.S. Economy; General Principles for Success; Governments; Universities; Industry; 2: Divided We FallChallenges; Collaboration Models; Examples of Successful Biomedical Collaborations; Biomarkers Consortium; Predictive Safety Testing Consortium; SNP and SAEC Consortia; Principles of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People ; Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References; 4: The Changing Face of Innovation in Drug DiscoveryIntroduction; Core Objectives of the Drug Discovery Process; Major Innovations in Technology Have Advanced Drug Discovery; Target Identification and Target Validation; Hit Identification: The First Stage in Drug Hunting; Lead Optimization: A Field to Which Companies Must Commit Major Amounts of Human and Financial Resources; Preclinical Assessment: Select the First-in-Class and/or Best-in-Class Drug Candidate for Clinical Development; An Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery; Future Perspectives: Where Is Innovation Leading?References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies; Probe Discovery in Public Domain; Effective Management of Academia-Pharma Collaborations; Concluding Remarks; References; 6: A Perspective on the Evolution of Collaborative Drug Discovery and Future ChallengesEvolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities; Maryland Industrial Partnerships (MIPS) Program; Funding for Collaborations with Academia; New Initiatives to Transform University-Industry Collaborations
• Sommario/riassunto: Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving d